FDMT - 4D Molecular Therapeutics, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

FDMT

4D MOLECULAR THERAPEUTICS, INC.

NASDAQ

$12.59

▲ UP 0.24% (0.03)

KEY STATISTICS

Market Cap$658.94 M

52w High$16.93

52w Low$6.96

Dividend Yield—

Frequency—

P/E-4.90

Volume603.57K

Shares Out.52.28M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

David H. Kirn

COMPENSATION 2026

Salary$667,252

Stock Awards$0

Incentive Plan Pay$560,597

All Other Comp.$744

Total$2,051,343

ABOUT

SECTOR

Healthcare

WENT PUBLIC

December 11, 2020

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

196

PRICE TARGET

Target High$37.00

Target Low$20.00

Target Median$32.00

Target Consensus$29.67

UPCOMING EARNINGS

DateNov 10, 2026

DayTuesday

Rev. Est.$3.54M

NOV

TUE

ETFS HOLDING THIS STOCK

ETFS HOLDING

113

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

68.90%

HOLDERS

214

TOP 8 OF 214 · RANKED BY POSITION SIZE

Ra Capital Management, L.P.

5.7M sh

$42.4M

Janus Henderson Group Plc

Goldman Sachs Group Inc

PRICE

$12.59 ▲ UP 0.24% (+$0.03)

About 4D Molecular Therapeutics, Inc.

https://www.4dmoleculartherapeutics.com ↗

4D Molecular Therapeutics is a clinical-stage gene therapy company developing AAV vector-based treatments for ophthalmology, cardiology, and pulmonology, with multiple candidates in Phase 1/2 trials and collaborations with major biotech firms.

INDUSTRY

Biotechnology

A PRODUCT 4D MOLECULAR THERAPEUTICS, INC. IS KNOWN FOR

4D-150

An investigational genetic medicine delivering sustained anti-VEGF proteins via a single low-dose intravitreal injection to treat wet AMD and DME, aiming to reduce the need for frequent treatments.

COMPETITORS

COMPETITOR

4D Molecular Therapeutics in 2025

SENTIMENT: ± MIXED

RESTRUCTURING · JULY 2025

4D Molecular Therapeutics Lays Off 25% of Workforce to Accelerate Phase 3 Eye Gene Therapy Trial

In a significant strategic move, 4D Molecular Therapeutics laid off a quarter of its employees in June 2025, a decision made public in early July. This restructuring was aimed at saving approximately $15 million annually and streamlining operations to focus resources on its late-stage and most promising asset, the eye gene therapy 4D-150. The company simultaneously announced an accelerated timeline for its 4FRONT-1 Phase 3 trial for 4D-150 in wet age-related macular degeneration, with topline data expected sooner than previously anticipated.

RESTRUCTURING · JANUARY 2025 AND JULY 2025 · IN PROGRESS

4DMT Restructures to Hyper-Focus on Late-Stage Gene Therapy Candidate 4D-150, Slashing Pipeline and Workforce

4D Molecular Therapeutics executed a significant strategic shift in 2025 by terminating two clinical programs and halting investment in three others to exclusively prioritize its late-stage assets, primarily 4D-150 for wet AMD. This pipeline overhaul was followed by a corporate restructuring that included a 25% reduction in its workforce to align resources with the accelerated development and potential commercialization of its lead candidate.

Latest News

GLOBENEWSWIRE · OCT 5, 2026

4DMT to Host Investor Day on October 21, 2026

Company to share insights on the advancing clinical profile and commercial vision for 4D-150 Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C.

READ ARTICLE